# US 10,869,921 B2 · Compositions and methods to treat AIDS > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,869,921 B2 - Document ID: US10869921B2 - Status: Granted - Kind: B2 - Application number: 16/180,519 - Filed: 2018-11-05 - Published: 2019-05-30 - Granted: 2020-12-22 - Earliest claimed: 2013-03-15 - Assignees: University of Massachusetts - Applicants: University of Massachusetts - Inventors: Shan Lu; Shixia Wang - Web page: https://patentgrep.com/patent/US10869921B2 ## CPC - A61K 39/21: Retroviridae, e.g. equine infectious anemia virus - A61K 39/12: Viral antigens - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - C07K 14/005: from viruses - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - A61K 2039/53: {DNA (RNA) vaccination} - A61K 2039/54: {characterised by the route of administration} - A61K 2039/545: {characterised by the dose, timing or administration schedule} - A61K 2039/575: {humoral response} - A61K 2039/70: {Multivalent vaccine} - C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against HIV are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different HIV envelope glycoproteins. The synthetic, codon-optimized DNAs encoding one or more HIV proteins are a combination of different nucleic acids, such as DNA plasmids, generated from primary isolate DNA of different HIV major group genetic clades and/or different proteins. HIV polypeptide compositions for inducing an immune response against HIV are also disclosed. Methods for using the polypeptide compositions before, at the same time as, and/or after administration of the DNA compositions are provided. ## Claims ### Claim 1 A composition comprising: a first synthetic nucleic acid molecule comprising a nucleotide sequence that has at least 90% identity to the nucleotide sequence of SEQ ID NO:1; and a second synthetic nucleic acid molecule comprising a nucleotide sequence that has at least 90% identity to the nucleotide sequence of SEQ ID NO:7. ### Claim 2 A composition comprising: a first polypeptide comprising an amino acid sequence that has at least 90% identity to the amino acid sequence of SEQ ID NO: 2; a second polypeptide comprising an amino acid sequence that has at least 90% identity to the amino acid sequence of SEQ ID NO: 8; and an adjuvant. ### Claim 3 (depends on 1) The composition of claim 1, wherein the first synthetic nucleic acid molecule comprises a nucleotide sequence that has at least 92% identity to the nucleotide sequence of SEQ ID NO:1 and the second synthetic nucleic acid molecule comprises a nucleotide sequence that has at least 92% identity to the nucleotide sequence of SEQ ID NO:7. ### Claim 4 (depends on 1) The composition of claim 1, wherein the first synthetic nucleic acid molecule comprises a nucleotide sequence that has at least 95% identity to the nucleotide sequence of SEQ ID NO:1 and the second synthetic nucleic acid molecule comprises a nucleotide sequence that has at least 95% identity to the nucleotide sequence of SEQ ID NO:7. ### Claim 5 (depends on 1) The composition of claim 1, wherein the first synthetic nucleic acid molecule comprises a nucleotide sequence that has at least 97% identity to the nucleotide sequence of SEQ ID NO:1 and the second synthetic nucleic acid molecule comprises a nucleotide sequence that has at least 97% identity to the nucleotide sequence of SEQ ID NO:7. ### Claim 6 (depends on 1) The composition of claim 1, wherein the first synthetic nucleic acid molecule comprises a nucleotide sequence that has at least 99% identity to the nucleotide sequence of SEQ ID NO:1 and the second synthetic nucleic acid molecule comprises a nucleotide sequence that has at least 99% identity to the nucleotide sequence of SEQ ID NO:7. ### Claim 7 (depends on 1) The composition of claim 1, wherein one of the synthetic nucleic acid molecules comprises a nucleotide sequence that has at least 95% identity to the nucleotide sequence of SEQ ID NO: 7. ### Claim 8 (depends on 1) The composition of claim 1, wherein one of the synthetic nucleic acid molecules comprises a nucleotide sequence that has at least 97% identity to the nucleotide sequence of SEQ ID NO: 7. ### Claim 9 (depends on 1) The composition of claim 1, wherein one of the synthetic nucleic acid molecules comprises a nucleotide sequence that has at least 99% identity to the nucleotide sequence of SEQ ID NO: 7. ### Claim 10 (depends on 1) The composition of claim 1, wherein the composition further comprises a carrier or an adjuvant. ### Claim 11 (depends on 2) The composition of claim 2, wherein the first polypeptide comprises an amino acid sequence that has at least 92% identity to the amino acid sequence of SEQ ID NO: 2 and the second polypeptide comprises an amino acid sequence that has at least 92% identity to the amino acid sequence of SEQ ID NO: 8. ### Claim 12 (depends on 2) The composition of claim 2, wherein the first polypeptide comprises an amino acid sequence that has at least 95% identity to the amino acid sequence of SEQ ID NO: 2 and the second polypeptide comprises an amino acid sequence that has at least 95% identity to the amino acid sequence of SEQ ID NO: 8. ### Claim 13 (depends on 2) The composition of claim 2, wherein the first polypeptide comprises an amino acid sequence that has at least 97% identity to the amino acid sequence of SEQ ID NO: 2 and the second polypeptide comprises an amino acid sequence that has at least 97% identity to the amino acid sequence of SEQ ID NO: 8. ### Claim 14 (depends on 2) The composition of claim 2, wherein the first polypeptide comprises an amino acid sequence that has at least 99% identity to the amino acid sequence of SEQ ID NO: 2 and the second polypeptide comprises an amino acid sequence that has at least 99% identity to the amino acid sequence of SEQ ID NO: 8. ### Claim 15 (depends on 2) The composition of claim 2, wherein the composition further comprises a carrier. ### Claim 16 (depends on 2) The composition of claim 2, wherein the adjuvant is QS-21, incomplete Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or alum. ### Claim 17 (depends on 16) The composition of claim 16, wherein the adjuvant is incomplete Freund's adjuvant. ### Claim 18 (depends on 2) The composition of claim 2, wherein the composition further comprises one or more nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, CCR5 receptor antagonists, integrase inhibitors, or maturation inhibitors. ### Claim 19 (depends on 18) The composition of claim 18, wherein the protease inhibitor comprises one or more of atazanavir, darunavir, fosamprenavir, or ritonavir. ### Claim 20 (depends on 2) The composition of claim 2, wherein one or both of the first or the second polypeptide comprises a conservative amino acid substitution in the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 8, respectively.